Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
IUB Ballerine MIDI intrauterine contraceptive device
21040000268
|
IUB Ballerine MIDI intrauterine contraceptive device | Contraceptive Devices | Appliances | No data available |
|
IVA Anamix Infant powder
0913234A0BBAAAA
|
IVA Anamix powder infant formula | Powder infant formula (0913234) | Nutrition and Blood | No data available |
|
IVA Anamix Junior powder
0913223A0BBAAAA
|
IVA powder 28g protein equivalent per 100g | Powder 28g protein equivalent per 100g (0913223) | Nutrition and Blood | No data available |
|
IVA Maxamaid powder
090401000BBHLA0
|
Proprietary compound foods for special diets | Other food for special diet preparations | Nutrition and Blood | No data available |
|
Ivacaftor 25mg granules sachets sugar free
0307000S0AAADAD
|
Ivacaftor | Ivacaftor | Respiratory System | No data available |
|
Ivacaftor 50mg granules sachets sugar free
0307000S0AAABAB
|
Ivacaftor | Ivacaftor | Respiratory System | No data available |
|
Ivacaftor 75mg granules sachets sugar free
0307000S0AAACAC
|
Ivacaftor | Ivacaftor | Respiratory System | No data available |
|
Ivelip 10% emulsion for injection 500ml bottles
090300000BBAYA0
|
Proprietary compound I/V nutriton | Other intravenous nutrition preparations | Nutrition and Blood | No data available |
|
Ivelip 20% emulsion for injection 500ml bottles
090300000BBAXAU
|
Proprietary compound I/V nutriton | Other intravenous nutrition preparations | Nutrition and Blood | No data available |
|
Ivemend 115mg powder for solution for infusion vials
0406000AEBBAAAA
|
Ivemend | Fosaprepitant | Central Nervous System | No data available |
|
Ivemend 150mg powder for solution for infusion vials
0406000AEBBABAB
|
Ivemend | Fosaprepitant | Central Nervous System | No data available |
|
Ivermectin 15mg tablets
0505060I0AAADAD
|
Ivermectin | Ivermectin | Infections | No data available |
|
Ixazomib 2.3mg capsules
0801050CCAAAAAA
|
Ixazomib | Ixazomib | Malignant Disease and Immunosuppression | No data available |
|
Ixazomib 3mg capsules
0801050CCAAABAB
|
Ixazomib | Ixazomib | Malignant Disease and Immunosuppression | No data available |
|
Ixazomib 4mg capsules
0801050CCAAACAC
|
Ixazomib | Ixazomib | Malignant Disease and Immunosuppression | No data available |
|
Ixchiq vacc inj 0.5ml vials
1404000AYBBAAAA
|
Ixchiq | Chikungunya vaccine | Immunological Products and Vaccines | No data available |
|
Ixekizumab 80mg/1ml inj pre-filled disposable devices
1305030G0AAABAB
|
Ixekizumab | Ixekizumab | Skin | No data available |
|
Ixekizumab 80mg/1ml inj pre-filled syringes
1305030G0AAAAAA
|
Ixekizumab | Ixekizumab | Skin | No data available |
|
Izinova concentrate for oral solution
0106050B0BGAAA0
|
Izinova | Bowel cleansing solutions | Gastro-Intestinal System | No data available |
|
J Collis Browne's tablets
0104020N0BEABAF
|
J Collis Browne's | Opium and morphine | Gastro-Intestinal System | No data available |
|
J.L. Bragg's Medicinal Charcoal biscuits
1902070E0BBAAAA
|
J.L.Bragg's Charcoal | Charcoal | Other Drugs and Preparations | No data available |
|
Jackson's Extra Strength All Fours 100mg/5ml oral solution
0309020G0BMAAAB
|
Jackson's All Fours (Guaifenesin) | Guaifenesin | Respiratory System | No data available |
|
Jackson's Lemon linctus
0309020H0BIAAAE
|
Jackson's Glycerol, Lemon and Honey | Glycerol | Respiratory System | No data available |
|
Jackson's The Original All Fours 50mg/5ml oral solution
0309020G0BMABAL
|
Jackson's All Fours (Guaifenesin) | Guaifenesin | Respiratory System | No data available |
|
Jackson's Vapour Rub
030800000BDBRA0
|
Proprietary compound preparation BNF 0308000 | Other aromatic inhalation preparations | Respiratory System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.